GLP-1 Agonist in Anesthesia
Last year, JAMA and a Kaiser Family Foundation poll reported that 1 in 8 US adults used a glucagon-like peptide 1 (GLP-1) agonist medication. At the same time, the FDA has issued a warning on the increased risk of pulmonaryaspiration associated with patients taking GLP-1 medications who require general anesthesia or deep sedation.GLP-1 agonists delay Gastrointestinal motility and increase the risk of aspiration, nausea, and abdominaldistension. Patients who have recently started or intermittently use these medications are at particularly high risk of experiencing these symptoms during general anesthesia.
GLP-1 Medications and Pulmonary Aspirations
In the absence of randomized controlled trials to properly evaluate the risk of pulmonary aspiration in patient staking GLP-1 medications (Ozempic, Wegovy, Munjaro, etc), institutions are creating their own guidelines that may still put certain patients at risk of complications during general anesthesia. Studies that look at withholding these medications for a few days or weeks before a procedure have not been powered enough to ensure this practice completely reduces the risks of complications. At the same time, stopping these medications can also result inhyperglycemia and other postsurgical complications, such as infections.
Just like you wouldn’t use a paralytic without Neostigmine or give Rocuronium (Roc) or Vecuronium (Vec) without Sugammadex available, why would anyone use an airway device that couldn’t prevent complications from aspiration?
NEVAP Aspire Subglottic ET Tubes
The NEVAP Aspire Subglottic ET tube is the only device that allows for immediate, safe, and consistent drainage of the space around the tube. When aspiration happens, draining the area above the cuff is a proven strategy to prevent complications. Yankhaurs and suction catheters can only suction the back of the mouth and can never evacuate the space directly above the cuff. If your patient is intubated with the Aspire ETT, aspiration can be removed by simply connecting the suction to the built-in suction line. The Aspire utilizes a built-in channel and a multiport tissue spacer to ensure suctioning is effective and atraumatic to patients. Countless clinicians have already utilized these tubes during procedures, and tens of thousands of these devices are used each year.
If you’ve never seen or used one of these tubes before, now is a good time to start. Airway management begins with the right tools and ends with better outcomes.
Contact us today to get your free samples and a demonstration of this superior product or BUY TODAY!
NeVap Multiport Subglottic Suction Endotracheal Tube, 10/box
NeVap Multiport Subglottic Suction Endotracheal Tube
- B090010 6.0 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
- B090011 6.5 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
- B090012 7.0 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
- B090013 7.5 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
- B090014 8.0 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
- B090015 8.5 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
- B090016 9.0 mm ASPIRE SUBGLOTTIC SUCTION DRAINAGE ETT
Frequently Asked Questions (FAQ)
What is the difference in the NEVAP Aspire Subglottic ET Tube from a Traditional ET Tube?
The NEVAP Aspire ETT has a built-in channel designed to allow drainage of the space above the cuff. The Aspire ETT utilizes a built-in tissue spacer surrounded by 24 ports to ensure fluids that would otherwise be aspirated are removed with impunity. These tubes are already a standard for patients who require long-term intubation; however, they can also be valuable for many different patient subsets in all clinical settings.
Traditional ETTs do not.
Does the NEVAP Aspiree ETT require special training or in-service?
No, simply connect the tube to standard OR suction. This allows for an efficient workflow, as the patient is intubated and protected against aspiration, without the need for additional lines or attachments.
Who benefits the most from the NEVAP?
Everyone benefits from it. The patient benefits from the added protection; clinicians in the OR, as well as the PACU or ICU, no longer need to worry about unexpected aspiration while the patient is under their care, and hospitals avoid unnecessary complication costs, which can exceed $20,000 per patient¹.
¹ https://www.atsjournals.org/doi/10.1513/AnnalsATS.201611-867OC